ADRA1 agonists(Adrenergic receptor alpha-1 agonists), ADRA2 agonists(Adrenergic receptors alpha-2 agonists), β1-adrenergic receptor agonists(Beta-1 adrenergic receptor agonists)

+ [2]

Therapeutic Areas

Otorhinolaryngologic DiseasesRespiratory Diseases

Active Indication

Nasal Obstruction

Inactive Indication

Congestion of nasal mucosaRhinitis, Allergic

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Qinghai Lake Pharmaceutical Co. Ltd.

Inactive Organization

Schering-Plough Corp.

Drug Highest PhaseApproved

First Approval Date

US (30 Oct 1980),

Congestion of nasal mucosaRhinitis, Allergic

Regulation-

Structure

Molecular FormulaC10H15NO

InChIKeyKWGRBVOPPLSCSI-WCBMZHEXSA-N

CAS Registry90-82-4

View All Structures (2)

Clinical Trials associated with Pseudoephedrine Sulfate

NCT05697328 / RecruitingNot ApplicableIIT

Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy

The purpose of this research is to study whether the use of pseudoephedrine can help prevent middle ear trauma during HBOT. Pseudoephedrine is an approved drug that is used for temporary relief of nasal or sinus pain and pressure.

Start Date31 Jan 2023

Sponsor / Collaborator

John Muir Health

NCT05692869 / CompletedNot Applicable

A Study to Investigate Continuous Blood Pressure Monitoring Using Traditional Device (ABPM) Versus Novel Devices (Biobeat and Aktiia)

The main purpose of this study in healthy participants is to find out whether the traditional ambulatory blood pressure monitor (ABPM) and newer wearable devices (EmbracePlus smartwatch device, Biobeat chest patch device, and Aktiia wrist device) will accurately pick up changes in blood pressure caused by 2 different medications (propranolol and pseudoephedrine). The study will last about 29 days excluding the screening period of 28 days.

Start Date31 Jan 2023

Sponsor / Collaborator

Eli Lilly & Co.

ACTRN12622000542796 / CompletedPhase 2IIT

Exploring the activity of pseudoephedrine in treating retrograde ejaculation following retroperitoneal lymph node dissection (RPLND) in survivors of testicular cancer - Part B

Start Date06 Sep 2022

Sponsor / Collaborator

Peter MacCallum Cancer Institute

100 Clinical Results associated with Pseudoephedrine Sulfate

100 Translational Medicine associated with Pseudoephedrine Sulfate

100 Patents (Medical) associated with Pseudoephedrine Sulfate

1,261

Literatures (Medical) associated with Pseudoephedrine Sulfate

01 Nov 2024·BJU International

Pseudoephedrine for ejaculatory dysfunction after retroperitoneal lymph node dissection in testicular cancer

Article

Author: Thomas, Benjamin ; O'Haire, Sophie ; Conduit, Ciara ; Moody, Mary ; Hutchinson, Amanda D. ; Ahmad, Gulfam ; Hong, Wei ; Sim, Ie‐Wen ; Lawrentschuk, Nathan ; Leonard, Matt ; Dhillon, Haryana M. ; Lewin, Jeremy ; Tran, Ben

ObjectiveTo assess the impact of ejaculatory dysfunction (EjD; failure of emission or retrograde ejaculation) on health‐related quality of life (HRQoL) after retroperitoneal lymph node dissection (RPLND) for testicular cancer and explore the efficacy of pseudoephedrine hydrochloride as treatment.Patients and MethodsIn a single arm, phase II trial, patients at ≥6 months after RPLND were invited to complete patient‐reported outcome measures (European Organisation for Research and Treatment of Cancer [EORTC] quality of life questionnaire [QLQ]‐30‐item core, EORTC QLQ‐testicular cancer‐26, and Brief Male Sexual Function Inventory) evaluating HRQoL and sexual function in follow‐up (ACTRN12622000537752/12622000542796). If EjD was reported, post‐ejaculatory urine ± semen analysis was undertaken. In eligible patients, pseudoephedrine hydrochloride 60 mg was administered orally every 6 h for six doses. The primary endpoint was sperm count >39 million sperm/ejaculate (>5th centile) following treatment. The trial was powered to detect a clinically relevant 36% achieving sperm count of >39 million sperm/ejaculate. Secondary endpoints included semen volume >1.5 mL, total motile sperm count, safety, and HRQoL impacts.ResultsOf the 58 patients enrolled, the median (interquartile range [IQR]) age was 35 (29–41) years, with a median (IQR) of 37 (18–60) months from RPLND. EjD was reported in 33 (57%), including 27/52 (52%) receiving follow‐up at our centre. There were no differences in global HRQoL; however, role functioning (P = 0.045), sexual problems (P < 0.005), and sexual enjoyment (P = 0.005) was poorer if EjD was present. In all, 24/33 (73%) patients with EjD consented to pseudoephedrine treatment. Of 22 evaluable patients, four (18%) achieved a sperm count of >39 million/ejaculate (P = 0.20), and four (18%) had a semen volume of >1.5 mL (P = 0.20). There was a mean increase of 105 million sperm/ejaculate (P = 0.051) and 1.47 mL increase in semen volume (P = 0.01). No safety concerns arose.ConclusionEjaculatory dysfunction is common after RPLND but did not impact global HRQoL in our cohort. Pseudoephedrine improved EjD for some; however, its efficacy was lower than expected. Pseudoephedrine may be considered on an individualised basis.

01 Oct 2024·Journal of Surgical Research

Evaluation of Oral Vasoactive Medications to Maintain Mean Arterial Pressure in Spinal Cord Injury

Article

Author: Bardes, James ; Sestito, Michael ; Petros, Karen ; Victory, Jack ; Niemann, Britney ; Smida, Tanner ; Zarfoss, Erika

INTRODUCTIONAn acute spinal cord injury (SCI) results in significant morbidity worldwide. Guidelines recommend mean arterial pressure (MAP) augmentation to prevent hypoperfusion. Although there is no consensus on a single vasoactive agent for MAP augmentation, intravenous vasopressors are commonly utilized, requiring an intensive care unit (ICU). Beyond the financial burden for patients, ICU stays require significant hospital system resource utilization. Oral vasoactive agents, such as pseudoephedrine and midodrine, are also utilized for MAP augmentation, but little data on their efficacy are available. This study investigates the use and dosing of oral vasoactive agents as an alternative in MAP augmentation in SCI.MATERIALS AND METHODSAdult SCI patients were retrospectively investigated. Total daily vasoactive dose, treatment efficacy, and ICU length of stay were evaluated.RESULTS141 patients were evaluated, with 7.1% receiving oral agents alone, and 80.9% receiving vasopressors who either transitioned to pseudoephedrine, pseudoephedrine plus midodrine, or no oral agent. Patients receiving oral agents trended toward decreased ICU stay, but there was no difference in vasopressor duration. Similar MAP goal success rates were found between groups. A variety of initial and maximum daily doses of PO agents were used. Median doses were 120 mg pseudoephedrine and 30 mg midodrine. Early initiation of pseudoephedrine resulted in shorter ICU stays.CONCLUSIONSThis study demonstrated shorter ICU length of stay and similar MAP goal success with PO agents as compared to vasopressors. This may indicate these medications could be utilized to decrease the financial burden placed on patients and the health care system from lengthy ICU courses. This study is limited by a small sample size and variable agent dosing.

21 Aug 2024·Journal of Analytical Toxicology

Over-the-counter medications encountered in the postmortem pediatric population from 2010–2020

Article

Author: Midthun, Kari M ; Swatek, Jennifer L ; Marco, Stephanie M

AbstractIn forensic toxicology, the pediatric population requires special focus when evaluating positive findings because of the many toxicokinetic and toxicodynamic differences (e.g., metabolic capabilities, body size, etc.) between the pediatric and adult populations. In particular, the administration of over-the-counter (OTC) medications needs careful consideration, as dosages given to the pediatric population (0 days–18 years), particularly those given to individuals <5 years of age, tend to be lower than those given to individuals closer to adulthood. Postmortem pediatric data from 11 years (2010–2020) was compiled. A total of 1413 positive cases contained one or more of the following common OTC medications: antihistamines (brompheniramine, chlorpheniramine, diphenhydramine, doxylamine and pheniramine), pain relievers (acetaminophen, naproxen, ibuprofen and salicylates), cold/flu medications (dextro/levomethorphan, guaifenesin, ephedrine and pseudoephedrine), gastrointestinal aids (dicyclomine and loperamide) and/or sleep aids (melatonin). Antihistamines, cold/flu medications and pain relievers are the most common classes of drugs encountered in the postmortem pediatric population. To evaluate trends, three main age groups were created: ≤5 years old (5 U, birth-5 years old), middle childhood (MC, 6–11 years old), and early adolescence (EA, 12–18 years old). When considering the data, it must be noted that many of these drugs may be co-administered in single and/or multi-drug formulations. In addition, some drugs may have a variety of uses, e.g. antihistamines may also be used as sleep aids. Of note, the prevalence of cases involving those aged 6–11 years old was far less than their younger and older pediatric counterparts. With the widespread availability of OTC medications, unintentional overdoses, recreational misuse and suicidal overdoses can occur in the vulnerable, pediatric population.

News (Medical) associated with Pseudoephedrine Sulfate

28 Mar 2024

·www.prnewswire.com

U.S. News Reveals the 2024 Best OTC Medicine & Health Products

2024 edition includes 30+ new product categories evaluated, new dermatologist expert panel reviewers. WASHINGTON, March 28, 2024 /PRNewswire/ -- U.S. News & World Report, the global authority in health care rankings and consumer advice, today published the second annual Best OTC Medicine & Health Products. The latest edition of the rankings features 132 categories, with 33 brand new over-the-counter product categories included this year. The brands with the most No. 1 products among the 2024 rankings are Nature Made, followed by CeraVe and Neutrogena; the companies with the most No. 1 products are Kenvue Inc., followed by Haleon plc and Pharmavite LLC. "With hundreds of thousands of over-the-counter health products on the market in the U.S., the U.S. News annual Best OTC Medicine & Health Products rankings help consumers choose the best OTC products for themselves and their families," said Sumita Singh, general manager of Health at U.S. News. "Continuing our commitment to offer consumers trusted, data-backed ratings and rankings to help with their health care decisions, the 2024 evaluation features statistically 'best' brands evaluated by hundreds of pharmacists and dermatologists." In partnership with global market research firm The Harris Poll, U.S. News surveyed 354 pharmacists and 122 dermatologists practicing in the United States regarding 132 product categories such as adult and children's cough suppressants, men's and women's multivitamins, fish oil/omega-3 supplements, baby formula, face washes and cleansers, and retinol creams and serums. This was the first year that dermatologists were included in the survey, which was administered online in February 2024. To determine the rankings, panelists selected their top three recommended brands within each product category assigned to them. The brands that were highly ranked most often were ranked No. 1 for the corresponding product categories. U.S. News awarded the designations of Best OTC Medicine & Health Products only to those brands that satisfy U.S. News' statistical assessment of performance on the survey. Based on U.S. News' analysis, some product categories were awarded more than one winner. Some popular 2024 product category winners, ranked No. 1, evaluated by pharmacists include: Children's Cough Medicines: Children's Delsym Cough Drops: Halls Cough Suppressants: Delsym Decongestants, Oral: Sudafed (Pseudoephedrine) Diarrhea Medicines and Treatments: Imodium Eye Vitamins: Bausch + Lomb Ocuvite Fish Oil/Omega-3 Supplements: Nature Made Laxatives: MiraLAX Multivitamins for Men: Centrum Multivitamins for Women: One A Day Nausea Remedies: Dramamine Nausea Saline Nasal Sprays: Ayr Sore Throat Sprays: Chloraseptic Some popular 2024 product category winners, ranked No. 1, evaluated by dermatologists include: Eye Cream for Wrinkles: La Roche-Posay Face Moisturizers: CeraVe Face Washes and Cleansers: CeraVe Hand Creams: Neutrogena Moisturizers With SPF: CeraVe Night Creams: CeraVe Retinol Creams and Serums: Neutrogena Sunscreen for Face: EltaMD Vitamin C Serum: La Roche-Posay Vitamins for Hair Growth: Nutrafol Wrinkle Creams: Neutrogena Those looking to choose a health product that's right for them or their child should consult a medical professional as part of their decision-making process. For the full rankings, visit U.S. News' 2024 Best OTC Medicine & Health Products. Explore more of the 2024 product rankings using #BestOTCProducts on Facebook, Instagram, TikTok and X (formerly Twitter). About U.S. News & World Report U.S. News & World Report is the global leader in quality rankings that empower consumers, business leaders and policy officials to make better, more informed decisions about important issues affecting their lives and communities. A multifaceted digital media company with Education, Health, Money, Travel, Cars, News, Real Estate, Careers and 360 Reviews platforms, U.S. News provides rankings, independent reporting, data journalism, consumer advice and U.S. News Live events. More than 40 million people visit USNews.com each month for research and guidance. Founded in 1933, U.S. News is headquartered in Washington, D.C. About The Harris Poll The Harris Poll is a global consulting and market research firm that delivers proven intelligence for transformational times. Responsible for one of the longest-running surveys in the United States, Harris Poll provides unique context and social insights based on having analyzed public opinion, motivations, and social sentiment since 1963. It works with clients in three primary areas: building modern corporate reputation, crafting brand strategy and performance tracking, and data-driven thought leadership. It also delivers industry-leading healthcare insights expertise, specializing in research with patients, caregivers, nurses, physicians, specialists (across over 50 therapeutic areas) payers, hospital decision makers, policy makers, and pharmacists. Its mission is to provide insights and guidance to help leaders make the best decisions possible. To learn more, please visit . SOURCE U.S. News & World Report, L.P.

13 Sep 2023

·www.fiercepharma.com

It's unanimous: FDA panel says decongestant drug phenylephrine does not work

The FDA may soon remove over the counter use of a decongestant drug used in approximately 250 common cold and flu products because of its ineffectiveness. For decades, hundreds of oral decongestant products containing phenylephrine have been available in the United States over the counter. But on Tuesday, an FDA advisory committee agreed by a 16-0 vote that the ingredient does not work. Now it is up to the FDA to decide whether to ban over-the-counter use of widely used cold and flu decongestants such as Sudafed, Nyquil, Benadryl, Mucinex and Tylenol, which contain phenylephrine. Products that include the ingredient—roughly 250 of them—generated approximately $1.8 billion in sales in 2022, the FDA said. Data presented to the committee on Monday and Tuesday showed that phenylephrine performed no better than placebo in relieving congestion when given by mouth. Phenylephrine is designed to reduce the swelling of blood vessels but the committee concluded that when it is taken orally not enough of the drug reaches the nasal passages. “We clearly have better options in the over-the-counter space to help our patients, and the studies do not support that this is an effective drug,” Maria Coyle, chairwoman of the Nonprescription Drugs Advisory Committee (NDAC) and a professor of pharmacy at Ohio State University, said during meeting deliberations. Nasal sprays that contain phenylephrine are still effective, the FDA said. The drug also is effective for dilating the eyes and for use during surgery. Revoking phenylephrine’s OTC designation would be disruptive, forcing pharmacies to clear shelves of meds containing the ingredient and requiring companies to reformulate many of their cold and flu products. “The burdens created from decreased choice and availability of these products would be placed directly onto consumers and an already-strained U.S. healthcare system,” the Consumer Healthcare Products Association, said in a release. “The CHPA encourages the panel to consider the real-world experience and needs of consumers when making decisions that will have such broad implications.” Phenylephrine is one of two oral decongestants available without prescription. Sales of the other, pseudoephedrine, were restricted in 2006 because it can be misused to make methamphetamine. Products with pseudoephedrine are still available OTC but are often behind store counters or locked away, out of the reach of consumers. There also are limitations on how many pills that can be purchased in a store visit. The restrictions led to a boom in products containing phenylephrine. But soon after their rise in popularity, the FDA’s scrutiny of phenylephrine began. In 2007, the NDAC came to a similar conclusion on its ineffectiveness. While four subsequent studies showed the ineffectiveness of phenylephrine when taken as a pill, there was enough variability in the results to raise questions about how the studies were conducted. “We do believe that the original studies were methodologically unsound and do not match today’s standard,” Peter Starke, who first led the FDA’s review of phenylephrine, said to the committee. “By contrast, we believe the new data are credible and do not provide evidence that oral phenylephrine is effective.”

15 Dec 2022

·www.prnewswire.com

China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19

HAIKOU, China, Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 (First Edition) (hereinafter referred to as the Catalogue) published by People's Daily on December 12, 2022. Recently, China has completely ended its strict quarantine and zero case policies in response to COVID-19 pandemic in the past three years. Out of concern about the spread of the epidemic, people began to hoard many related drugs. The Chinese government has issued the Catalogue to guide people to take drugs accordingly. A series of drugs of our Company are listed in the catalog, and the demand is huge. Our modern Traditional Chinese Medicine (TCM) anti-virus product: Andrographolide has been listed in the Catalogue Our cold medicine: Naproxen Sodium and Pseudoephedrine Hydrochloride Sustained Release Tablets (brand name, Pusen OK), in which the compound ingredient pseudoephedrine is in line with the cold symptom relief medicine recommended in the Catalog It was announced in many places in China in recent days that pharmacies will no longer register or upload customer information on "four types of drugs", which includes anti-fever, cough, antiviral and antibiotic drugs. This will benefit the sales of our main products, roxithromycin and cefaclor The market demand for our masks has also increased significantly Ms. Li Zhilin, CEO of China Pharma said: " With the liberalization of epidemic risk control measures across China, the number of infected people may rise rapidly. The public's need in keeping certain epidemic prevention materials and related drugs has been dramatically increasing. As a professional pharmaceutical manufacturer for nearly 30 years, we will continue to spare no effort to provide high-quality products to protect people's health." About China Pharma Holdings, Inc. China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty pharmaceutical company that develops, manufactures, and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit . The Company routinely posts important information on its website. Safe Harbor Statement Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation. SOURCE China Pharma Holdings, Inc.

100 Deals associated with Pseudoephedrine Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
D05649	Pseudoephedrine Sulfate	R01BA02	DB00852

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nasal Obstruction	CN	Qinghai Lake Pharmaceutical Co. Ltd.	01 Jan 1992

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AUA2018	Not Applicable	Diabetes Mellitus	-	Imipramine+pseudoephedrine	bwxgarexxi(qemcoypjun) = yhhrsjlpwt joqmkbcfay (ucvdvpmpjl ) View more	-	01 Apr 2018
NCT00704496 (CTgov)	Phase 3	Rhinitis \| Sleep	34	Pseudoephedrine (Placebo)	liosvoehsv(mwapyxtmll) = hqjndkhnbi shxtkylpqm (wmovxtfclm, nocvxrwklz - pasmwrdldk) View more	-	18 Oct 2017
				Pseudoephedrine (Pseudoephedrine)	liosvoehsv(mwapyxtmll) = gutsimksad shxtkylpqm (wmovxtfclm, kjgyfoecxr - hyowmobllc) View more
NCT01028014 (CTgov)	Not Applicable	-	56	Pseudoephedrine (Pseudoephedrine 120mg ER Daily)	vcfqnfnpjh(gcywcbrakv) = igcpuzbodm zsfptweuox (kjfhainayk, ivirakaywl - mwstosckpt) View more	-	05 Sep 2011
				Solifenacin (Solifenacin 5mg Daily)	vcfqnfnpjh(gcywcbrakv) = kbhmqdryin zsfptweuox (kjfhainayk, pcvbdsacic - vmncwnntuj) View more
NCT00377403 (CTgov)	Phase 4	Acute respiratory infections \| Acute sinusitis	172	Saline spray (0.65%)+Pseudoephedrine Sustained Action+Acetaminophen+amoxicillin+guaifenesin+Dextromethorphan hydrobromide (Intervention Arm)	vqkgusgjsp(wpcbdzpbfg) = fklrvjmglv gbrdpjbfhy (xsakhanals, zmwypkbcaj - xpdsxyrfve) View more	-	29 Jun 2011
				Saline spray (0.65%)+Pseudoephedrine Sustained Action+Acetaminophen+guaifenesin+Dextromethorphan hydrobromide (Symptomatic Treatments Only)	vqkgusgjsp(wpcbdzpbfg) = ncvmnfxljc gbrdpjbfhy (xsakhanals, qzfiwrlrzv - szlpyilufk) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis